American Journal of Ophthalmology Case Reports (Jun 2023)
Successful treatment of idiopathic retinal vasculitis with rituximab in two patients
Abstract
Purpose: To describe results of treatment of idiopathic retinal vasculitis with intravenous rituximab. Observations: We present two patients with idiopathic retinal vasculitis who required steroid-sparing therapy and achieved steroid-free remission with intravenous rituximab. Rituximab was used as a first-line steroid-sparing agent after steroids in one patient and as a second-line steroid-sparing agent in the other patient. Both patients achieved steroid-free remission of disease with follow up of at least one year after rituximab initiation. Conclusions and importance: Rituximab achieved steroid-free remission in two patients with idiopathic retinal vasculitis. It should be considered as a treatment option in these patients.